BR112012020304A2 - complexo que alveja tecido, uso de um complexo que alveja tecido, método de tratamento de um corpo de animal humano ou não humano, composição farmacêutica, e, kit - Google Patents

complexo que alveja tecido, uso de um complexo que alveja tecido, método de tratamento de um corpo de animal humano ou não humano, composição farmacêutica, e, kit

Info

Publication number
BR112012020304A2
BR112012020304A2 BR112012020304A BR112012020304A BR112012020304A2 BR 112012020304 A2 BR112012020304 A2 BR 112012020304A2 BR 112012020304 A BR112012020304 A BR 112012020304A BR 112012020304 A BR112012020304 A BR 112012020304A BR 112012020304 A2 BR112012020304 A2 BR 112012020304A2
Authority
BR
Brazil
Prior art keywords
targeting complex
tissue targeting
human
kit
treating
Prior art date
Application number
BR112012020304A
Other languages
English (en)
Other versions
BR112012020304B1 (pt
Inventor
Thomas Ramdahl
Original Assignee
Algeta Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algeta Asa filed Critical Algeta Asa
Publication of BR112012020304A2 publication Critical patent/BR112012020304A2/pt
Publication of BR112012020304B1 publication Critical patent/BR112012020304B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

complexo que alveja tecido, uso de um comlexo que alveja tecido, método de tratamento de um corpo de animal humano ou não humano, composição farmacêutica, e, kit. a presente invenção fornece um complexo que alveja tecido que compreende uma porção que alveja tecido, um ligando que contém hidroxipiridinona octadentado e o íon de um radionuclídeo de tório emissor alfa. a invenção adicionalmente fornece métodos terapêuticos que utilizam tais complexos. métodos de sua produção e uso, e kits e composições farmacêuticas que compreendem tais complexos.
BR112012020304A 2010-02-12 2011-02-14 complexo que alveja tecido, uso de um complexo que alveja tecido e composição farmacêutica BR112012020304B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1002508.8A GB201002508D0 (en) 2010-02-12 2010-02-12 Product
PCT/EP2011/052158 WO2011098611A2 (en) 2010-02-12 2011-02-14 Alpha-emitting complexes

Publications (2)

Publication Number Publication Date
BR112012020304A2 true BR112012020304A2 (pt) 2016-04-26
BR112012020304B1 BR112012020304B1 (pt) 2019-12-10

Family

ID=42110714

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012020304A BR112012020304B1 (pt) 2010-02-12 2011-02-14 complexo que alveja tecido, uso de um complexo que alveja tecido e composição farmacêutica

Country Status (26)

Country Link
US (2) US9724436B2 (pt)
EP (2) EP2533817B1 (pt)
JP (2) JP5878483B2 (pt)
KR (1) KR101931382B1 (pt)
CN (1) CN103608043B (pt)
AU (1) AU2011214281B2 (pt)
BR (1) BR112012020304B1 (pt)
CA (1) CA2789433C (pt)
CY (1) CY1120362T1 (pt)
DK (2) DK3417883T3 (pt)
EA (1) EA026305B1 (pt)
ES (2) ES2674875T3 (pt)
GB (1) GB201002508D0 (pt)
HR (2) HRP20180996T1 (pt)
HU (2) HUE038013T2 (pt)
IL (2) IL221416A (pt)
LT (2) LT3417883T (pt)
MX (1) MX343405B (pt)
NZ (1) NZ601867A (pt)
PL (2) PL2533817T3 (pt)
PT (2) PT3417883T (pt)
RS (2) RS57360B1 (pt)
SG (1) SG183279A1 (pt)
SI (2) SI2533817T1 (pt)
TR (1) TR201809149T4 (pt)
WO (1) WO2011098611A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007272604B2 (en) 2006-07-10 2013-08-01 The Regents Of The University Of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
EP2470513B1 (en) 2009-08-24 2014-10-08 Lumiphore, Inc. Macrocyclic hopo chelators
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes
CN105025933B (zh) * 2013-01-14 2019-03-26 分子制药洞察公司 三嗪类放射性药物和放射性显影剂
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
GB201310028D0 (en) 2013-06-05 2013-07-17 Algeta Asa Pharmaceutical preparation
MA41176A (fr) * 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques
WO2016106241A1 (en) * 2014-12-22 2016-06-30 Lumiphore, Inc. Functionalized linear ligands and complexes thereof
GB201504064D0 (en) 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
CN108778347A (zh) 2016-03-24 2018-11-09 拜耳制药股份公司 放射性药物配合物
BR112018075554A2 (pt) * 2016-06-10 2019-10-01 Bayer As complexos radiofarmacêuticos
WO2018153975A1 (en) 2017-02-24 2018-08-30 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
US10377778B2 (en) 2017-12-13 2019-08-13 Sciencons AS Lead and thorium compounds
CA3110754A1 (en) 2018-08-28 2020-03-05 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
US20220040338A1 (en) * 2018-10-16 2022-02-10 Nant Holdings Ip, Llc Alpha Emitter Compositions And Methods
US20220125960A1 (en) 2019-02-21 2022-04-28 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
EP3927339A1 (en) 2019-02-22 2021-12-29 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
AR119479A1 (es) 2019-07-25 2021-12-22 Bayer As Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
CN116745323A (zh) 2021-01-22 2023-09-12 拜耳股份有限公司 Lrrc15抗体及其缀合物
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011475A1 (en) 1988-05-25 1989-11-30 The United States Of America, As Represented By Th Macrocyclic chelates and methods of use thereof
JPH089553B2 (ja) 1989-06-19 1996-01-31 アクゾ・エヌ・ヴエー α粒子放出を使用する放射免疫療法
SG52470A1 (en) 1992-04-13 1998-09-28 Dow Chemical Co Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
US5624901A (en) 1994-04-15 1997-04-29 The Regents Of The University Of California 3-hydroxy-2(1H)-pyridinone chelating agents
ES2221929T3 (es) * 1995-06-14 2005-01-16 The Regents Of The University Of California Agentes quelantes 3-hidroxi-2(1h)-piridinona.
AU729515B2 (en) 1996-10-17 2001-02-01 Immunomedics Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
WO1998027209A1 (en) 1996-12-18 1998-06-25 Emory University Polycationic oligomers
NO310544B1 (no) 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
NO314537B1 (no) 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
AU4906901A (en) 2000-02-25 2001-09-17 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US7893223B2 (en) * 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
GB0213261D0 (en) 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
US20030228256A1 (en) 2002-06-11 2003-12-11 Inverardi Luca A. Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations
US20030086868A1 (en) 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
ITMI20022411A1 (it) 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US20060228297A1 (en) 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease
EP1617876B1 (en) * 2003-04-15 2014-05-14 Algeta AS Thorium-227 for use in radiotherapy of soft tissue disease
EP1735013B1 (en) 2004-02-20 2012-02-08 Algeta ASA Alpha- and beta-emitting hydroxyapatite particles
WO2006003123A2 (en) * 2004-06-25 2006-01-12 The European Community, Represented By The European Commission Radionuclides for medical use
GB0423565D0 (en) 2004-10-22 2004-11-24 Algeta As Formulation
AU2007272604B2 (en) * 2006-07-10 2013-08-01 The Regents Of The University Of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
CA2660800C (en) 2006-08-15 2016-03-01 The Regents Of The University Of California Luminescent macrocyclic lanthanide complexes
WO2008085064A2 (en) * 2007-01-11 2008-07-17 Ge Healthcare As Hydroxypyridinone chelating agents, their metal complexes and their use as mri contrast agents
JP2013515744A (ja) * 2009-12-24 2013-05-09 ルミフォア，インコーポレイテッド 放射性医薬品錯体
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201007353D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
GB201007354D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
GB201105298D0 (en) 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes

Also Published As

Publication number Publication date
PT2533817T (pt) 2018-06-29
RS57360B1 (sr) 2018-08-31
NZ601867A (en) 2014-11-28
PL2533817T3 (pl) 2018-08-31
JP6125599B2 (ja) 2017-05-10
HUE038013T2 (hu) 2018-09-28
PL3417883T3 (pl) 2020-08-24
TR201809149T4 (tr) 2018-07-23
CN103608043B (zh) 2017-07-28
EA026305B1 (ru) 2017-03-31
IL243303A (en) 2017-09-28
WO2011098611A3 (en) 2015-07-02
EP3417883B1 (en) 2020-03-25
CA2789433C (en) 2019-01-15
RS60314B1 (sr) 2020-07-31
IL221416A (en) 2016-03-31
HRP20200826T1 (hr) 2020-08-07
JP2016029114A (ja) 2016-03-03
CN103608043A (zh) 2014-02-26
EP2533817A2 (en) 2012-12-19
EP3417883A1 (en) 2018-12-26
GB201002508D0 (en) 2010-03-31
LT3417883T (lt) 2020-07-10
US9724436B2 (en) 2017-08-08
MX343405B (es) 2016-11-03
SI2533817T1 (en) 2018-08-31
US20170319721A1 (en) 2017-11-09
LT2533817T (lt) 2018-07-10
JP5878483B2 (ja) 2016-03-08
HUE049465T2 (hu) 2020-09-28
KR101931382B1 (ko) 2018-12-20
US10682430B2 (en) 2020-06-16
BR112012020304B1 (pt) 2019-12-10
AU2011214281B2 (en) 2014-01-16
CA2789433A1 (en) 2011-08-18
AU2011214281A1 (en) 2012-08-30
EP2533817B1 (en) 2018-03-28
HRP20180996T1 (hr) 2018-08-10
US20130183235A1 (en) 2013-07-18
IL221416A0 (en) 2012-10-31
CY1120362T1 (el) 2019-07-10
EA201290712A1 (ru) 2014-12-30
MX2012009260A (es) 2013-02-07
SI3417883T1 (sl) 2020-07-31
KR20120130769A (ko) 2012-12-03
SG183279A1 (en) 2012-09-27
DK3417883T3 (da) 2020-06-08
JP2013519658A (ja) 2013-05-30
ES2794853T3 (es) 2020-11-19
WO2011098611A2 (en) 2011-08-18
IL243303A0 (en) 2016-04-21
ES2674875T3 (es) 2018-07-04
DK2533817T3 (en) 2018-07-16
PT3417883T (pt) 2020-06-01

Similar Documents

Publication Publication Date Title
BR112012020304A2 (pt) complexo que alveja tecido, uso de um complexo que alveja tecido, método de tratamento de um corpo de animal humano ou não humano, composição farmacêutica, e, kit
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
MX2021007468A (es) Compuestos que participan en la union cooperativa y usos de los mismos.
MY195474A (en) Single Domain Antibody and Derivative Proteins Thereof Against Programmed Death Ligand (Pdl1)
BR112016002000A2 (pt) Diagnóstico e terapia de câncer envolvendo células-tronco tumorais
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
CO2018003134A2 (es) Composiciones para el cuidado bucal que comprenden un aminoácido básico, una combinación de fuentes de iones de zinc y un sistema quelante
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
BR112016006978A2 (pt) inibidores de tirosina quinase de bruton
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
ECSP10010735A (es) Compuestos químicos 251
ECSP14014544A (es) Compuestos terapéuticamente activos y sus métodos de uso
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
IN2015DN00376A (pt)
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
TR201902439T4 (tr) Fukoz analogları kullanarak in vivo protein fukosilasyonunun inhibisyon yöntemleri .
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
MX2015012528A (es) Inhibidores macrociclicos de cinasa inducibles por sal.
BR112015026238A8 (pt) composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112021008012A2 (pt) Conjugados de anticorpo de cisteína engenheirada-fármaco com ligantes contendo peptídeo
BR112012022243A2 (pt) terapias inibidoras de autografia baseadas em tioxantona para tratar câncer
EA201591773A1 (ru) Макроциклические ингибиторы rip2-киназы

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAYER AS (NO)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/02/2011, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/02/2011, OBSERVADAS AS CONDICOES LEGAIS